Human Embryonic Stem Cells Market Forecasts to 2030 – Global Analysis By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Multipotent Stem Cells, Oligopotent Stem Cells, Unipotent Stem Cells and Other Types), Source, Application and By Geography

Human Embryonic Stem Cells Market Forecasts to 2030 – Global Analysis By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Multipotent Stem Cells, Oligopotent Stem Cells, Unipotent Stem Cells and Other Types), Source, Application and By Geography

According to Stratistics MRC, the Global Human Embryonic Stem Cells Market is accounted for $1.8 billion in 2023 and is expected to reach $3.8 billion by 2030 growing at a CAGR of 11.2% during the forecast period. The inner cell mass of a human embryo during the blastocyst stage, usually 5-7 days after conception, is when human embryonic stem cells, a kind of pluripotent stem cell, are generated. The amazing capacity of these cells to develop into almost any form of cell in the human body is well recognized. They have a tremendous potential for application in regenerative medicine and research in addition to playing a critical function in early human development. It is crucial to ensure the efficacy and security of human embryonic stem-based therapeutics, to produce and deploy them, rigorous quality control procedures and safety evaluations are essential.

According to the article from DVC Stem published in August 2022, it was observed that the goal of stem cell therapy for Parkinson's disease is to replace destroyed brain cells with healthy, undifferentiated stem cells.

Market Dynamics

Driver

Growing technological advancements

The market for human embryonic stem cells has greatly benefited from technological improvements. With these developments, working with these cells has substantially improved in terms of effectiveness, safety, and usability, making them a more attractive alternative for research and possible therapeutic applications. Researchers can more accurately replicate the natural milieu of cells in the human body thanks to the development of three-dimensional (3D) culture models. As a result, human embryonic stem cells differentiation into certain cell types for regenerative therapy is improved. With the help of innovations like CRISPR-Cas9, the hESC genome may now be precisely edited, revolutionizing the field of gene editing. Hence all the above factors boost the market growth.

Restraint

Concerns about the ethics of using embryonic stem cells

Studies looking into the therapeutic potential of embryonic stem cells (ESC) are linked to a number of moral dilemmas including the killing of human embryos. Lack of appropriate government laws that specify what can be supported in the development of therapies using embryo-based stem cells may eventually limit the market's growth to some extent. Federal laws are further necessary due to the complexity of the legislation in this field so that researchers, scientists, and pharmaceutical firms can develop ESC treatment and accelerate its commercialization.

Opportunity

Rising incidence of chronic diseases

There is a high demand for efficient therapies due to the rising prevalence of chronic diseases including diabetes, cardiovascular disease, neurological disorders, and autoimmune ailments. These diseases, which frequently include permanent tissue damage, may be treated using human embryonic stem cells -based therapy. Tissue deterioration and organ dysfunction are frequently seen in patients with chronic illnesses and are a useful resource for tackling the long-term effects of chronic illnesses because regenerative medicine techniques use them to repair, replace, or regenerate damaged tissues and organs. To determine the safety and effectiveness of human embryonic stem-based treatments for particular chronic conditions, clinical studies have been started.

Threat

Tendency of immune rejection

Immune rejection may cause human embryonic stem cells-derived cell treatments to fail. Transplanted cells may be attacked and killed if the immune system of the recipient recognizes them as alien, making the therapy useless and it may limit the long-term advantages of therapy based on human embryonic stem cells. Even if the initial engraftment is effective, the persistent immune response may cause the transplanted cells to gradually disappear, decreasing the therapeutic effect's longevity thus hampering the market growth.

Covid-19 Impact

The pandemic interfered with laboratory research projects, particularly stem cell projects. The development of human embryonic stem cells research and clinical trials was hampered by the temporary closure or reduction of activities at several research organizations. Moreover, the progress of these trials was slowed down by site closures, challenges with patient recruiting, and safety worries and made safety and efficacy of medical research and therapy development even more important. This might result in human embryonic stem cells -based medicines receiving more thorough safety evaluations which hinder the market growth.

The totipotent stem cells segment is expected to be the largest during the forecast period

The totipotent stem cells segment is estimated to have a lucrative growth, as these are special kind of stem cell and all cell types in the human body, including extraembryonic and embryonic tissues, may be formed from these cells, which is extraordinary. They vary from pluripotent stem cells, though, in that the latter can develop into all bodily cell types except for extraembryonic tissues. Understanding how totipotent stem cells develop into distinct cell types can be aided by research employing these cells.

The stem cell biology research segment is expected to have the highest CAGR during the forecast period

The stem cell biology research segment is anticipated to witness the highest CAGR growth during the forecast period, as these are living things that can develop into many kinds of cells. Various stem cell types are also employed in medical treatments. Numerous biopharmaceutical firms have recently conducted substantial research into these compounds, which have numerous uses at the clinical stage for a variety of disorders, including cancer and neurological ailments. Due to the growing frequency of disorders like Parkinson's disease, cancer, and others, stem cell biology research will see improved growth. The market under study is thus anticipated to see a significant growth rate throughout the projected period as a result of these reasons.

Region with largest share

North America is projected to hold the largest market share during the forecast period owing to the growing government emphasis on drug discovery, healthcare investment, and advanced infrastructure for the development of technologies in drug discovery, as well as expanding development strategies used by several business verticals in the area. Furthermore, it is predicted that strict regulatory rules for medication research and related clinical studies would spur the market. The launch of biological and bio similar drugs by biopharmaceutical manufacturers in the US is another factor that is anticipated to fuel the market's expansion.

Region with highest CAGR

Europe is projected to have the highest CAGR over the forecast period, owing to stringent laws governing the use of human embryonic stem cells for both research and therapy. The creation and endorsement of stem cell-based medicines are regulated by national regulatory organizations and the European Medicines Agency (EMA). For instance, in Europe, human embryonic stem cells -based clinical studies have been carried out or are now being done for a range of illnesses, including spinal cord injury, heart disease, and degenerative diseases. The purpose of these trials is to assess the efficacy and safety of stem cell-based treatments. To advance human embryonic stem cells research and turn it into practical applications, partnerships between academic institutions, biotech firms, and healthcare facilities are typical in this region which encourages the market.

Key players in the market

Some of the key players profiled in the Human Embryonic Stem Cells Market include PeproTech Inc., Astellas Pharma Inc., Merck KGaA, Lineage Cell Therapeutics Inc., PromoCell GmbH, Thermo Fisher Scientific, ViaCyte, Inc., Takara Bio Inc., STEMCELL Technologies Inc, Cell Cure Neurosciences LTD, CellGenix GmbH, ESI BIO, Lonza, Kite Pharma, Cynata, Sumanas, Inc., LifeCell, International Stem Cell Corporation, Genea BioCells and Geron

Key Developments

In October 2023, Astellas Pharma Inc. and BioLabs Global, Incand Mitsui Fudosan, announced that they have agreed on a tri-party memorandum of understanding to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan, world-renowned science hubs.

In October 2023, Merck launches new collaboration with United Nations-Guided Global Initiative on ageing to support carers; new training course provides critical skills for unpaid family carers and coincides with European Carers Day and Family Caregiver awareness month in the U.S.

In September 2023, Thermo Fisher Scientific expands St. Louis manufacturing for complex biologic treatments for diseases ranging from cancers to auto immune conditions to rare genetic disorders.

In September 2023, Thermo Fisher Scientific Inc. the world leader in serving science, and the National Minority Quality Forum (NMQF), an independent not-for-profit research and education organization, announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials (ARC).

Types Covered
• Totipotent Stem Cells
• Pluripotent Stem Cells
• Multipotent Stem Cells
• Oligopotent Stem Cells
• Unipotent Stem Cells
• Other Types

Sources Covered
• Bone Marrow
• Adult Body Tissues
• Embryonic Tissues
• Fetal tissues
• Differentiated Somatic Cells
• Other Sources

Applications Covered
• Stem Cell Biology Research
• Regenerative Medicine
• Tissue Engineering
• Toxicology Testing
• Blood Disease Treatment
• Treatment of Cardiovascular Disease
• Other Applications

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements